

## ASX Announcement

24 November 2022

### Results of 2022 AGM

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Analytica Ltd advises the results of its 2022 Annual General Meeting.

All resolutions were carried on a poll. Details of the resolutions, the proxies received, and the votes cast on the poll in respect of each resolution are set out in the attached results.

This announcement has been authorised for release to ASX by the Board

For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

### About Analytica Limited

Analytica is a product development and commercialisation company, based in Queensland, Australia, focussed on Class I and II medical device products.

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia and has CE mark and USFDA 510(k) clearance for the treatment of urinary incontinence.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of mild to moderate pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

Analytica is also the developer of the Enhanced Infusion System (EIS), a combination of patented technologies developed under the project names AutoStart and AutoFlush. The EIS is a simple and inexpensive IV add-in technology to reduce nursing monitoring costs, reduce embolism risk, improve infection control, and automatically restart flow after medication delivery during intravenous fluid infusion.



# ANALYTICA LIMITED

ANNUAL GENERAL MEETING  
Thursday, 24 November, 2022

## RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	ADOPTION OF THE REMUNERATION REPORT	N	195,013,066 81.63%	6,881,663 2.88%	36,993,117 15.49%	27,006	256,144,727 97.38%	6,881,663 2.62%	1,477,007	Carried
2	RE ELECTION OF MR ROSS MANGELSDORF AS A DIRECTOR	NA	963,334,144 95.72%	6,112,111 0.61%	36,993,117 3.68%	0	1,030,889,555 99.41%	6,112,111 0.59%	0	Carried
3	APPROVAL OF ENHANCED PLACEMENT CAPACITY	NA	957,434,910 95.16%	6,647,596 0.66%	42,023,117 4.18%	333,749	1,030,020,321 99.36%	6,647,596 0.64%	333,749	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item